Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profile
Authors:
- 19 July 2023
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 191, 113246
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Systemic Therapy for Melanoma: ASCO GuidelineJournal of Clinical Oncology, 2020
- Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trialThe Lancet Oncology, 2020
- ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines CommitteeAnnals of Oncology, 2020
- ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines CommitteeAnnals of Oncology, 2020
- Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III MelanomaNew England Journal of Medicine, 2020
- Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019European Journal of Cancer, 2020
- Expanded Access as a source of real‐world data: An overview of FDA and EMA approvalsBritish Journal of Clinical Pharmacology, 2020
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV MelanomaNew England Journal of Medicine, 2017
- Completion Dissection or Observation for Sentinel-Node Metastasis in MelanomaNew England Journal of Medicine, 2017
- Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trialThe Lancet Oncology, 2016